Core Scientific Inc (CORZ.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates when the first AMD-campus bond prices inside 9% and Pecos energizes on schedule. Cheap, non-dilutive project capital validates the 15.3% yield-on-cost spread, which in turn makes converting a slice of AMD's 1,925MW reservation financeable rather than aspirational. Contracted revenue potential expands, the market applies a data-centre cap rate instead of a miner's discount, and REIT-structure speculation returns. Per-share value compounds well beyond the mid-thirties despite warrant dilution.

The bear case starts with a financing door that will not open. If high-yield spreads widen while an AI capex digestion phase questions neocloud credit, project bonds price above 10% or require an equity raise near $18, crystallizing dilution at the worst price. Construction slips, interest accrues against unbilled megawatts, and a counterparty wobble at CoreWeave or the Auburn tenant forces a punitive cap rate across the whole book. Negative book equity leaves no cushion; the residual claim halves.

The consensus trade is "miner becomes AI landlord, therefore rerate." Sell-side anchors cluster at $28-$35 on discounted 2028 EBITDA [4][16], while KBW's cap-rate work lands at $20-$23 [9]. The crowd treats the $24bn contracted headline as settled cash and the $6bn funding gap as a formality. Yet the stock fell 43.5% over ninety days and sits 12% below the rejected $20.40 bid.

Mild underpricing, with an important caveat. The market is anchored on GAAP wreckage: a TTM net loss near $1.44bn and negative book equity, which are dominated by a $1.05bn warrant fair-value mark and mining impairments, not operations [5]. H1 2026 operating cash flow was $230.9m and Q2 gross margin 43%. The blind spot cuts both ways, though: bulls quoting $35 ignore the 325m-to-508m diluted share wedge [1]. Fair value sits above today's price, but nearer $23-$26 than $35.

Pricing of the first AMD-campus project bond. A completed placement at a coupon inside roughly 9% would prove the $6bn gap is bridgeable without equity, collapsing the financing discount. Expect the attempt across 2027; first sign of repricing is spread guidance leaking before allocation.